Immunosenescence modulates radiation-induced anti-tumor immunity: implications for personalized immuno-oncology.
Age-related immune decline alters how radiation therapy triggers anti-tumor immunity, suggesting immune assessment should guide therapy choices in older patients.
This Frontiers in Immunology review explores how age-related immune decline (immunosenescence) affects the immunogenic potential of radiation therapy, with implications for radiotherapy-immunotherapy combinations in older cancer patients who comprise the majority of cancer cases. The authors propose that personalized immuno-oncology approaches should incorporate immune age assessment as a key variable in treatment selection and combination strategies.
What the study was
- Study design
- Narrative review
- Population
- Older adults with cancer receiving radiotherapy, with focus on immunosenescence effects on radiation-induced immune responses
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Frontiers in Immunology
Why it surfaced
Cross-topic review bridging aging/immunosenescence with immuno-oncology; relevant to both T8 (aging) and T6 (immunotherapy) watchlist areas; PMC open-access.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.